Zimmer Biomet Holdings, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ivan Tornos
- Full Time Employees
- 17,000
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 345 East Main Street Warsaw IN United States 46580
- IPO Date
- Jul 25, 2001
- CIK
- 0001136869
- Website
- zimmerbiomet.com
- Similar Companies
- Business
- Zimmer Biomet Holdings, Inc. designs, manufactures, and markets orthopedic reconstructive products; sports medicine, biologics, and extremities technologies; surgical and precision instruments; dental implants; and bone cement products worldwide. Founded in 1927 and headquartered in Warsaw, Indiana, the company operates globally with approximately 17,000 employees across 31 offices, serving healthcare professionals and patients through innovative implants, digital technologies, robotics, and analytics that span the patient journey from pre- to post-operative care. Core offerings include the ROSA Robotics platform for imageless knee and hip procedures; knee systems such as Persona and Oxford; hip solutions like Avenir Complete and Arcos Modular Revision; foot and ankle products including A.L.P.S. plating systems and recent Gorilla Pilon Fusion Plating and Phantom TTC Trauma Nail; trauma fixation devices; sports medicine technologies like BioCUE and AperFix; dental reconstructive implants; and integrated digital tools such as mymobility platform and AI-driven navigation. Recent developments encompass the October 2025 completion of the Monogram Technologies acquisition, enhancing semi- and fully autonomous robotics capabilities; the Paragon 28 acquisition bolstering foot and ankle and SET business growth; FDA clearance in November 2025 for ROSA Knee with OptimiZe; launches of the Magnificent Seven product suite; and plans for smart implants, next-generation ROSA robotics in 2026, and 20 new SCT products, driving projected 3.5-4.5% revenue growth in 2025 amid U.S. commercial specialization and ASC channel expansion.
Company News
Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery
Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term
Zimmer Biomet Lifts Annual Growth Despite Challenging Knee Market
Zimmer Biomet Holdings, Inc. (ZBH) Q3 2026 Earnings Call Transcript
Zimmer Biomet Stock Up on Q3 Earnings & Revenue Beat, '26 View Up
Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Zimmer Biomet (ZBH) Q3 Earnings and Revenues Beat Estimates
Zimmer Biomet Announces Third Quarter 2026 Financial Results
Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Zimmer Biomet to Preview the Next Era of Intelligent Orthopedic Surgery at AAHKS 2026
ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT
Should Value Investors Buy Zimmer Biomet (ZBH) Stock?
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results
Critical Review: Zimmer Biomet (NYSE:ZBH) and Butterfly Network (NYSE:BFLY)
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shareholders to Get $0.24 Quarterly Dividend
Zimmer Biomet Holdings, Inc. $ZBH Holdings Lifted by State Street Corp
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Critical Contrast: Zimmer Biomet (NYSE:ZBH) versus CapsoVision (NASDAQ:CV)